Figure 1.

Progression free survival (PFS) according to maintenace Bevacizumb (mBev) combined or not to hormonal therapy (HT) in hormonal receptor positive patients.

Fabi et al. BMC Cancer 2012 12:482   doi:10.1186/1471-2407-12-482
Download authors' original image